Artificial Intelligence (AI) has the potential to revolutionize how we find, develop, and deliver new life-saving therapies.

Join “State of the Art” host and Sidley partner Stephen Abreu as he speaks with Colin Hill, CEO and Co-Founder of Aitia. Together, they discuss the challenges and opportunities AI presents for the pharmaceutical industry, particularly how AI is accelerating the pace of drug discovery and its implications for the future of medicine.

The post AI Use in Drug Discovery appeared first on Data Matters Privacy Blog.